We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+31.47%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$294M
(-9.8%)
Cap. Flow
-$772M
Cap. Flow
% of AUM
-28.57%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
109
New
24
Increased
20
Reduced
34
Closed
23
Avg Time Held
3.5
quarters
Top 10 Avg Time Held
1.6
quarters
Top 20 Avg Time Held
2.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphatec Holdings
ATEC
|
+$39.7M |
| 2 |
Humana
HUM
|
+$32.6M |
| 3 |
Maze Therapeutics
MAZE
|
+$29.9M |
| 4 |
Avalo Therapeutics
AVTX
|
+$25.8M |
| 5 |
Alamar Biosciences
ALMR
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$78.9M |
| 2 |
Nuvalent
NUVL
|
+$71.8M |
| 3 |
CG Oncology
CGON
|
+$66.7M |
| 4 |
argenx
ARGX
|
+$55.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$46.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.44% |
| 2 | Miscellaneous | 3.68% |
| 3 | Financials | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Hemab Therapeutics
COAG
$1.37B
| $5.88M | 0.22% |
+160,000
| New | +$4.41M |
2026 Q2
0 quarters
|
|
77
GH Research
GHRS
$1.28B
| $5.57M | 0.21% |
+207,240
| New | +$4.33M |
2026 Q2
0 quarters
|
|
78
Waters Corp
WAT
$43B
| $5.27M | 0.19% |
+14,040
| New | +$4.79M |
2026 Q2
0 quarters
|
|
79
Research Alliance Corp III
RACC
$92.9M
| $4.28M | 0.16% |
+400,000
| New | +$4.17M |
2026 Q2
0 quarters
|
|
80
JATT II Acquisition Corp
JATT
$81.4M
| $2.84M | 0.11% |
+250,000
| New | +$2.66M |
2026 Q2
0 quarters
|
|
81
Pulmonx
LUNG
$76M
| $978K | 0.04% |
752,541
| – | – |
2022 Q4
14 quarters
|
|
|
YARW
82
Yarrow Bioscience
YARW
$160M
| $596K | 0.02% |
18,322
| – | – |
2026 Q1
1 quarter
|
|
|
KRSA
83
Korsana Biosciences, Inc. Common Stock
KRSA
$1.43B
| $532K | 0.02% |
+22,413
| New | +$509K |
2026 Q2
0 quarters
|
|
84
DELISTED
Apogee Therapeutics
APGE
| – | – |
-478,667
| Closed | -$40.3M | – |
|
85
BioMarin Pharmaceuticals
BMRN
$10.6B
| – | – |
-497,020
| Closed | -$28.1M | – |
|
86
Celcuity
CELC
$2.93B
| – | – |
-29,198
| Closed | -$3.33M | – |
|
|
87
CG Oncology
CGON
$5.47B
| – | – |
-984,783
| Closed | -$66.7M | – |
|
88
Compass Therapeutics
CMPX
$152M
| – | – |
-1,965,106
| Closed | -$10.4M | – |
|
89
Centene
CNC
$34.1B
| – | – |
-330,000
| Closed | -$10.8M | – |
|
|
CNTA
90
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-1,986,768
| Closed | -$78.9M | – |
|
91
CVS Health
CVS
$115B
| – | – |
-290,700
| Closed | -$20.9M | – |
|
92
Denali Therapeutics
DNLI
$2.82B
| – | – |
-296,324
| Closed | -$5.69M | – |
|
93
enGene Therapeutics
ENGN
$105M
| – | – |
-2,456,870
| Closed | -$16.7M | – |
|
94
Establishment Labs
ESTA
$1.73B
| – | – |
-463,600
| Closed | -$26.3M | – |
|
95
Fulcrum Therapeutics
FULC
$280M
| – | – |
-3,134,922
| Closed | -$24M | – |
|
96
Harrow
HROW
$1.04B
| – | – |
-156,419
| Closed | -$5.52M | – |
|
97
Illumina
ILMN
$40.7B
| – | – |
-229,215
| Closed | -$28.3M | – |
|
|
98
DELISTED
Nuvalent
NUVL
| – | – |
-700,429
| Closed | -$71.8M | – |
|
99
Penumbra
PEN
$12.6B
| – | – |
-105,352
| Closed | -$34.6M | – |
|
100
Praxis Precision Medicines
PRAX
$6.68B
| – | – |
-9,976
| Closed | -$3.21M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q2 2026 Portfolio in Review
As of Q2 2026, Braidwell held 109 positions worth $2.7B, down 9.8% from $3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Braidwell withdrew a net $772M in Q2 2026, closing 23 positions and reducing 34 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $78.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Humana worth $45.5M.
- Braidwell's largest Q2 2026 buy was Humana: 114,500 shares worth $45.5M.
- Braidwell added most to Alphatec Holdings in Q2 2026, an estimated $39.7M increase.
- Braidwell's biggest Q2 2026 reduction was argenx, cutting an estimated $55.5M.
- Braidwell fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $78.9M.
- Braidwell's ten largest holdings make up 32% of its $2.7B portfolio in Q2 2026.
- Braidwell opened 24 new positions and closed 23 in Q2 2026.
- Braidwell's portfolio value fell 9.8% quarter-over-quarter to $2.7B.
Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.